Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.78 |
| ▸ | ADRB2 | P07550 | 10/20 | 0.70 |
| ▸ | ADRB1 | P08588 | 10/20 | 0.70 |
| ▸ | ADRB3 | P13945 | 10/20 | 0.70 |
| ▸ | PRKCA | P17252 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.53 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13120035 | 0.91 | ALDH1A1 (0.66) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| SCHEMBL6928111 | 0.90 | ALDH1A1 (0.70) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| SCHEMBL1866116 | 0.90 | ALDH1A1 (0.70) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| SCHEMBL3391 | 0.90 | ALDH1A1 (0.70) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| SCHEMBL1866113 | 0.90 | ALDH1A1 (0.70) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| SCHEMBL22667354 | 0.89 | ADRB2 (0.68) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| SCHEMBL7037877 | 0.89 | MEN1 (0.72) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| SCHEMBL20515564 | 0.89 | ALDH1A1 (0.68) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| SCHEMBL26947493 | 0.89 | ALDH1A1 (0.68) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| SCHEMBL13573486 | 0.89 | ALDH1A1 (0.68) | ALDH1A1ADRB2ADRB1ADRB3PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3999051-A2 | USE OF A BENZOATE CONTAINING COMPOSITION TO TREAT NEURODEGENERATIVE DISORDERS | Rush University Medical Center (US) | 2022-05-25 | — | — | EP | claimed |
| CN-115298180-B | Compounds for treating or inhibiting recurrence of acute myeloid leukemia | 日本理化学研究所 | 2025-06-10 | — | — | CN | disclosed |
| US-11963960-B2 | Compounds for treating or inhibiting recurrence of acute myeloid leukemia | FLASH THERAPEUTICS, LLC (US) | 2024-04-23 | — | — | US | disclosed |
| US-11793737-B2 | Glyceryl and glycol acid compounds | MARY KAY INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11793737-B2 | Glyceryl and glycol acid compounds | MARY KAY INC. (US) | 2023-10-24 | — | — | US | disclosed |
| CN-116801869-A | Levodopa dosing regimen | 安慕尼制药公司 | 2023-09-22 | — | — | CN | disclosed |
| EP-4121430-A1 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | Flash Therapeuttics, LLC (US) | 2023-01-25 | — | — | EP | disclosed |
| CN-115298180-A | Compounds for treating or inhibiting recurrence of acute myeloid leukemia | 富雷旭医疗有限责任公司 | 2022-11-04 | — | — | CN | disclosed |
| US-20210299128-A1 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | RIKEN (JP) | 2021-09-30 | — | — | US | disclosed |
| US-20210299128-A1 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | RIKEN (JP) | 2021-09-30 | — | — | US | disclosed |
| US-20100004460-A1 | METHOD FOR PRODUCING 2-NITROIMIDAZOLE DERIVATIVE | POLA PHARMA INC (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20100004460-A1 | METHOD FOR PRODUCING 2-NITROIMIDAZOLE DERIVATIVE | POLA PHARMA INC (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20100004460-A1 | METHOD FOR PRODUCING 2-NITROIMIDAZOLE DERIVATIVE | POLA PHARMA INC (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2128140-A1 | METHOD FOR PRODUCING 2-NITROIMIDAZOLE DERIVATIVE | Pola Pharma Inc. (JP) | 2009-12-02 | — | — | EP | disclosed |
| WO-2007137128-A1 | GLYCERYL AND GLYCOL ACID COMPOUNDS | MARY KAY INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20070269391-A1 | GLYCERYL AND GLYCOL ACID COMPOUNDS | MARY KAY, INC. (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070269391-A1 | GLYCERYL AND GLYCOL ACID COMPOUNDS | MARY KAY, INC. (US) | 2007-11-22 | — | — | US | disclosed |
| US-5225590-A | Alkoxy methyl ether and alkoxy methyl ester derivatives | SYNTEX (U.S.A.) INC. (US) | 1993-07-06 | — | — | US | disclosed |
| EP-0187297-B1 | ALKOXY METHYL ETHER AND ALKOXY METHYL ESTER DERIVATIVES | SYNTEX (U.S.A.) INC. (US) | 1991-08-21 | — | — | EP | disclosed |
| EP-0187297-A2 | Alkoxy methyl ether and alkoxy methyl ester derivatives | SYNTEX (U.S.A.) INC. (US) | 1986-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070269391-A1 | GLYCERYL AND GLYCOL ACID COMPOUNDS | GLA, GK, UNG | ALDH1A1 512/4885ADRB2 3838/4885ADRB1 3694/4885 |
| US-11963960-B2 | Compounds for treating or inhibiting recurrence of acute myeloid leukemia | MCL1, FLT3, ABL1 | ALDH1A1 1260/4885ADRB2 4775/4885ADRB1 4737/4885 |
| US-11793737-B2 | Glyceryl and glycol acid compounds | GK, GLA, UGCG | ALDH1A1 451/4885ADRB2 3375/4885ADRB1 2704/4885 |
| US-20210299128-A1 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | MCL1, FLT3, ABL1 | ALDH1A1 1260/4885ADRB2 4775/4885ADRB1 4737/4885 |
| US-20100004460-A1 | METHOD FOR PRODUCING 2-NITROIMIDAZOLE DERIVATIVE | GALK1, HOGA1, DERA | ALDH1A1 519/4885ADRB2 2232/4885ADRB1 2755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.